Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, ...

In a report released today, Nicole Germino from Truist Financial maintained a Buy rating on Perspective Therapeutics (CATX – Research Report).

Wedbush reissued their outperform rating on shares of Perspective Therapeutics (NYSE:CATX – Free Report) in a report released ...

Perspective Therapeutics shares interim results for [212Pb]VMT-α-NET trial, showing promising safety, stable disease cases, and anti-tumor activity.

https://www.tipranks.com/news/the-fly/monopar-therapeutics-price-target-raised-to-40-from-22-at-h-c-wainwright Perspective Therapeutics (CATX) announced strategic ...

On Friday, Perspective Therapeutics, Inc. (NYSE:CATX) revealed updated interim results from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET. The data will be presented at the 2025 American ...

On Friday, Perspective Therapeutics, Inc. (NYSE:CATX) revealed updated interim results from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET. The data will be presented at the 2025 American Society of ...

Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers ...